Fig. 1: CONSORT diagram of patients included in the study. | Nature Medicine

Fig. 1: CONSORT diagram of patients included in the study.

From: Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial

Fig. 1

An illustration showing the number of patients screened for eligibility, reason for exclusion, the number enrolled and allocated to treatment, and those who either completed or discontinued perioperative therapy during the perioperative FLOT period, defined as the feasibility window. The enrolled cohort (n = 31) represents the ITT population.

Back to article page